eye disease News
-
ViGeneron announces follow-on collaboration with Daiichi Sankyo to develop a novel gene therapy for prevalent eye diseases
ViGeneron announces follow-on collaboration with Daiichi Sankyo to develop a novel gene therapy for prevalent eye diseases The companies agree a follow-on collaboration to evaluate ViGeneron’s adeno-associated virus vectors (vgAAVs) for delivering Daiichi Sankyo’s novel therapeutic protein to treat prevalent eye diseases ViGeneron GmbH, a next-generation gene therapy company, ...
-
LKC Technologies Announces Brazilian Health Regulatory Agency Approval for the UTAS™ System
LKC Technologies is pleased to announce that the Brazilian Health Regulatory Agency (Anvisa) has granted approval of the UTAS® device, making this a significant advancement in the preservation and enhancement of sight for patients in Brazil. LKC is collaborating with Oculus Brasil to provide physicians with broader access to LKC’s UTAS System and RETeval devices. Both are in extensive ...
-
Kala Announces Entry into Definitive Agreement to Sell EYSUVIS® and INVELTYS® to Alcon Inc.
ARLINGTON, Mass., May 23, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it has entered into a definitive agreement to sell its commercial portfolio and related intellectual property assets to Alcon Inc. ...
-
Big Data Meets Big Biology in San Diego: Some Takeaways
At the end of the 19th century, the German scientist Paul Ehrlich began to realize that certain chemicals could have highly specific effects on certain diseases. He began to write about the possibility that a drug could act like a magische kugel—magic bullet—that killed only the organism causing disease, and nothing else. Today, scientists are amassing a new arsenal of ...
-
ViGeneron announces research collaboration with Daiichi Sankyo to evaluate vgAAV for novel ophthalmic gene therapy
ViGeneron GmbH, a gene therapy company, today announced a research collaboration to utilize its novel engineered adeno-associated virus (vgAAV) vectors with Daiichi Sankyo Company, Limited (“Daiichi Sankyo”), for delivering a novel therapeutic protein to address an undisclosed target in a highly prevalent ophthalmic disease. ViGeneron’s vgAAVs enable the efficient transduction ...
-
ABK Biomedical Inc. Appoints Michael J. Mangano as President and CEO
ABK Biomedical announced today the appointment of Michael J. Mangano as president and chief executive officer. Mangano will be responsible for leading global business activities, including the rapid development, regulatory approval and commercialization of ABK’s unique medical device technologies. Mangano most recently served as president and CEO of ReShape Medical, a U.S. venture-backed ...
-
Eyevensys Announces the First-in-Human Treatment with its GroundBreaking EyeCET ElectroTransfection Technology for Eye Diseases
Eyevensys announces today that it has successfully treated the first patient in a first-in-human phase I/II trial of its lead candidate EYS606 for Non-Infectious Uveitis (NIU). The patient was treated in Paris, France at the Cochin Institute by Professor Antoine Brézin, the principal investigator of the trial, using the company’s novel EyeCET technology. EYS606 is the ...
By Eyevensys
-
ViGeneron signs global collaboration agreement for ophthalmic gene therapy development
Collaboration with Biogen to develop gene therapy for an undisclosed target to treat inherited eye disease, plus option for additional target The companies will use ViGeneron’s proprietary vgAAV technology to efficiently transduce target cells via intravitreal injections ViGeneron GmbH, a gene therapy company, today announced a global collaboration and licensing agreement with Biogen ...
-
TearLab Corporation Announces Adam Szaronos as President and Chief Executive Officer, and Jim Mazzo as Executive Chairman of the Board
TearLab Corporation, a global ophthalmic diagnostics company marketing point-of-care laboratory testing, today announced that Adam Szaronos has been appointed President and Chief Executive Officer by the company's Board of Directors, effective immediately. Mr. Szaronos has been instrumental in leading teams and bringing innovations to market to address unmet needs throughout eye care. Mr. ...
By SOFIE
-
LayerBio to Present Preclinical Results for Extended Release Glaucoma Formulation at ARVO
LayerBio will present preclinical study results at the Association for Research in Vision and Ophthalmology in Honolulu, Hawaii on Monday, April 30. These results demonstrate the therapeutic potential of its novel extended-release travoprost formulation using LayerBio's proprietary PolyNet delivery technology. LayerBio will present preclinical study results at the Association for Research in ...
-
Optos wins Artificial Intelligence in Health and Care Award to support the early detection of diabetes in NHS patients
Optos, a Fife based company and a world-leader in the design and manufacturing of advanced retinal imaging technology, has been awarded NHS funding to accelerate the implementation and validation of Artificial Intelligence (AI) to support the early detection of Diabetes related eye-disease into NHS Diabetic Eye Screening practices. The technology uses a machine learning algorithm to analyse ...
By Optos, Inc.
-
Regeneron to Report First Quarter 2022 Financial and Operating Results and Host Conference Call and Webcast on May 4, 2022
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2022 financial and operating results on Wednesday, May 4, 2022, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on ...
-
Gyroscope Therapeutics and the University of Pennsylvania Announce Research Agreement to Develop Gene Therapies for Serious Eye Diseases
LONDON – Friday 18 December 2020 – Gyroscope Therapeutics Limited, a clinical-stage gene therapy company focused on diseases of the eye, today announced the company has entered a sponsored research agreement with the University of Pennsylvania and the Penn Center for Advanced Retinal and Ocular Therapeutics (CAROT) to develop gene therapies for serious eye diseases that can lead ...
-
UNITY Biotechnology to Present Clinical Data at the Association for Research in Vision & Ophthalmology (ARVO) 2022 Annual Meeting
UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that clinical data results from the Phase 1 study of its lead senolytic candidate, UBX1325, in patients with diabetic macular edema and wet age-related macular degeneration will be presented at the Association for Research in ...
-
Digital Diagnostics Partners with Rapidly Scaling Medicare Advantage Organization, ArchWell Health
CORALVILLE, IOWA July 26, 2022 – Digital Diagnostics is proud to announce a partnership with ArchWell Health to bring IDx-DR, the autonomous AI diagnostic system for the detection of diabetic retinopathy (DR) – including diabetic macular edema (DME) – to ArchWell Health centers across the United States. “ArchWell Health is committed to improving patient outcomes and ...
-
World Diabetes Day
An estimated 415 million people are living with diabetes in the world. Diabetes is a chronic disease, that causes blood sugar levels in your body to become too high, either due to your body not being able to respond properly to insulin or due to your body not being unable to produce any at all. If left untreated, this can lead to serious complications such as heart attack, stroke, obesity, eye ...
-
Fulbright scholarship awarded to e-health expert
The award will enable Dr Yogesan Kanagasingam, Research Director for the Australian e-Health Research Centre (AEHRC), to spend four months at Stanford University School of Medicine developing and validating a new ‘non-invasive’ system to screen newborn babies. CSIRO Chief Executive, Dr Megan Clark, said Dr Kanagasingam’s work has application across a wide range of areas, ranging from remote, ...
-
New Ikarovec CSO Dr Katie Binley brings two decades of gene therapy expertise
Dr Peter Widdowson becomes CTO & company moves to Norwich Research Park Norwich, UK, July 29 2020 – Ikarovec, which is developing novel gene therapies to treat major ophthalmic indications, has appointed experienced gene therapy developer Dr Katie Binley as Chief Scientific Officer. At Oxford Biomedica for over 20 years, she worked on a range of ocular programmes, managing their ...
By Ikarovec
-
Glaukos Announces First Patient Enrolled in Phase 2 Clinical Trial for Dry Eye Disease
SAN CLEMENTE, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has enrolled the first patient into a Phase 2 clinical trial of GLK-301 for the treatment of signs and symptoms of Dry Eye Disease (DED). ...
-
DSM to acquire Vitatene S.A.U. to expand position in natural carotenoids
Royal DSM, the global Life Sciences and Materials Sciences company, announces today that it has signed an agreement with P&R Group (Italy) to acquire Vitatene S.A.U., based in León (Spain), a producer of natural carotenoids. The acquisition of Vitatene allows DSM to strengthen the natural carotenoids offerings of its nutrition business as consumer demand for natural products continues ...
By DSM
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you